Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Arthritis Research & Therapy

Research

Shunsuke Fukuyo¹  Shingo Nakayamada¹  Satoshi Kubo¹  Yoshiya Tanaka¹  Yusuke Miyazaki¹  Masanobu Ueno¹  Kentaro Hanami¹  Ippei Miyagawa² 

[1] The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, 807-8555, Kitakyushu, Japan;The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, 807-8555, Kitakyushu, Japan;Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany;Deutsches Zentrum für Immuntherapie (DZI), FriedrichAlexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany;

关键词: Palmoplantar pustulosis;    Pustulotic arthro-osteitis;    Guselkumab;    Adalimumab;   

DOI  :  10.1186/s13075-022-02934-3

 received in 2022-06-18, accepted in 2022-10-20,  发布年份 2022

来源: Springer

【 摘 要 】

ObjectivesWe compared the treatment effectiveness between guselkumab and adalimumab in patients with pustulotic arthro-osteitis (PAO). In addition, we performed peripheral blood immunophenotyping to elucidate the immunological background and analyzed the impact of therapeutic drugs to verify the validity of immunological phenotypes as therapeutic targets.MethodsPatients were treated with guselkumab 100 mg (guselkumab group; n = 12) and adalimumab 40 mg (adalimumab group; n = 13). Arthritis disease activity, skin lesion activity, and patient-reported outcomes (PROs) were evaluated and compared between the two groups. The retention rate and adverse events were evaluated. Comprehensive phenotyping of peripheral immune cells was performed in both groups, and phenotypes were compared before and after treatment.ResultsAt 6 months, both groups showed significant improvement in arthritis disease activity and PROs. In the guselkumab group, skin symptoms significantly improved. The 6-month continuation rates were 91.7% (11/12) and 69.2% (9/13) in the guselkumab and adalimumab groups, respectively. Adverse events occurred in 2/12 and 5/13 patients in the guselkumab (16.7%) and adalimumab (38.5%) groups, respectively. Peripheral blood immunophenotyping showed that the proportion of activated T helper (Th) 1 cells was significantly lower in patients with PAO than in healthy controls and that the proportion of activated Th17 cells was significantly higher in patients with PAO, which significantly decreased after treatment with guselkumab.ConclusionAlthough guselkumab and adalimumab have comparable efficacy for PAO, their impact on immunophenotypes varies.

【 授权许可】

CC BY   
© The Author(s) 2022. corrected publication 2022

【 图 表 】

Fig. 2

12302_2023_718_Article_IEq70.gif

Fig. 3

Fig. 2

42004_2023_830_Article_IEq4.gif

Fig. 2

40854_2023_458_Article_IEq14.gif

Fig. 1

Fig. 1

Fig. 1

Fig. 2